Martingale Asset Management L P Buys Shares of 24,712 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Martingale Asset Management L P bought a new stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) during the third quarter, Holdings Channel reports. The fund bought 24,712 shares of the company’s stock, valued at approximately $91,000.

A number of other institutional investors have also added to or reduced their stakes in the business. 49 Wealth Management LLC increased its position in Zentalis Pharmaceuticals by 81.7% during the 3rd quarter. 49 Wealth Management LLC now owns 22,558 shares of the company’s stock valued at $83,000 after purchasing an additional 10,145 shares during the period. Primecap Management Co. CA increased its position in Zentalis Pharmaceuticals by 21.6% during the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock valued at $5,513,000 after purchasing an additional 265,690 shares during the period. Intech Investment Management LLC purchased a new position in Zentalis Pharmaceuticals during the 3rd quarter valued at about $75,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Zentalis Pharmaceuticals by 126.3% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 229,138 shares of the company’s stock valued at $843,000 after buying an additional 127,868 shares in the last quarter. Finally, Aigen Investment Management LP bought a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at about $41,000.

Zentalis Pharmaceuticals Stock Up 0.9 %

ZNTL stock opened at $3.39 on Thursday. The firm has a 50 day moving average of $3.34 and a 200 day moving average of $4.65. The stock has a market capitalization of $241.57 million, a PE ratio of -1.36 and a beta of 1.84. Zentalis Pharmaceuticals, Inc. has a 52 week low of $2.66 and a 52 week high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. On average, equities research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.48 earnings per share for the current year.

Analyst Ratings Changes

ZNTL has been the topic of a number of recent analyst reports. Oppenheimer restated an “outperform” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Wedbush upgraded shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target on the stock in a report on Monday, August 12th. Finally, Guggenheim lowered their price target on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $10.00.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.